Nutshell Therapeutics’ NTS231 Clears FDA IND – First NRF2 Molecular Glue Degrader from China and Second Globally to Enter Clinical Development, Targeting KEAP1 to Block NRF2

Nutshell Therapeutics announced that NTS231, its independently developed covalent allosteric molecular glue degrader targeting NRF2, has received an IND clearance from the U.S. Food and Drug Administration (FDA), permitting clinical…